So far this year, Generis has bolstered its already deeply-experienced Life Sciences business development team with the appointment of Stefan Rupp, formerly VP of Global Business Development at ArisGlobal. He will head up sales across EMEA at Generis.
Commenting on his move to Generis, Stefan said, “This is a hugely exciting opportunity. Generis’s Intelligent Content Services platform, CARA™ has fantastic appeal not just in life sciences but in other process industries, manufacturing, automotive and more.
I am delighted to have the opportunity to join the Generis team at such a pivotal time in its growth and I look forward to making a sizeable impact with new customer acquisitions and an expanded market footprint.”
Stefan, based in Munich, southern Germany, joins George Waidell, based in the US who joined Generis last year. George is a seasoned life sciences business development executive, whose rich career to date has included senior roles at BioFortis, Liquent and Formpipe.
“Coming to work for a company with such a long and proven history of delivering solutions in life sciences, while continually innovating, has been extremely inspiring,” George says. “I’ve spent a long time in this industry, starting out as a ‘techie’, and the contrast has been eye-opening. The ease of use and configuration options available in CARA are incredible compared to other products. I’m also hugely impressed with the dedication of the entire Generis team in delivering every day (not just at the initial project) for our clients.
“The fact that CARA is a true cloud solution – built right from the ground up – and applicable across the full spectrum of life sciences use cases from regulatory, clinical, quality and safety to manufacturing and more, is significant – and timely given the scale of transformation companies now need to achieve,” he adds. “Crucially, CARA supports extensive integration of content right across the board, changing what companies can do with information. The platform is both very powerful and easy to use; pre-configured yet flexible and completely within the client’s control.”
Large organisations are increasingly turning to CARA to tie ‘data’ across business silos for efficiency and reuse, he notes. “Smaller companies like CARA too, for its scope to transform specific use cases (quality, regulatory documentation) – and the cost efficiency of being able to grow the platform’s use across other uses as their business evolves.”
Generis has also recently attracted a number of important partners with complementary expertise and service offerings including a collaboration with submissions management solutions and services company, Qdossier which was announced early January.
Reflecting on Generis’s position at the start of the New Year, James Kelleher, CEO, says, “With so much distressing news about the continuing pandemic and fears for public health, as well as the global economy, it is heartening that the Generis message is striking a chord in the market and is helping companies at a very challenging time. In particular we are proud to be peripherally involved in the battle against COVID-19, with the regulatory submission documents for both the AstraZeneca and Pfizer vaccines being managed in our CARA Life Science platform.
“Regulated industries face some very specific pressures, to keep their operations efficient while adhering to the strictest quality standards, and accelerating their speed to market. By bringing all kinds of critical content together in CARA, boosted by ever-increasing capabilities thanks to our partners, we’re helping companies make great inroads by streamlining the way they manage, access and combine critical information. We look forward to continuing to make a difference in 2021.”
Generis is a UK-headquartered developer of world-class Content and Regulatory Information Management technology for regulated industries globally.
Eight of the top 10 global life sciences companies rely on Generis’ flagship Intelligent Content Services platform, CARA™ for critical document and information management, including AbbVie, AstraZeneca, Biogen, Gilead, Bayer, Pfizer, and Merck KGaA.
Today Generis serves more than half a million users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com
Press Contact for Generis
Carina Birt, Sarum PR
+44 7970 006624